PTC-EM-AI Funding Program supports researchers advancing AI-discovered therapies through lead optimization and IND-enabling work to develop disease-modifying treatments for Alzheimer’s and related dementias.
Prevention RFP - Alzheimer's Drug Discovery Foundation supports researchers and clinicians conducting human studies of targeted interventions, combination therapies, and drug choices to reduce dementia risk.
The Tau Pipeline Enabling Program V funds translational research to develop and advance therapies targeting tauopathies, led by the Alzheimer's Association.
The Hoffman ALS Clinical Trial Awards Program supports researchers conducting early-stage trials of ALS treatments and imaging tracers to generate safety, dosing, and biomarker data for later development.
The Rainwater Charitable Foundation’s Medical Research Program funds innovative research on tauopathies, supporting studies that advance understanding and treatment of tau-related neurodegenerative diseases.